A new clinical trail has managed to spell new hope for children suffering from an aggressive form of childhood cancer, who now stand to benefit from a treatment that could hike the functionality of their immune system. About 60% of the kids with neuroblastoma have been successfully treated via a regular treatment routine, which includes chemotherapy.

The remaining, however, are classified as “high risk patients" and it is harder to treat them, and only about 30% of the patients actually manage to survive long-term. The new treatment routine will now look to help this category of children.

As announced by scientists from Cancer Research UK on Thursday, a new clinical trial using immunotherapy will be undertaken to try and develop a treatment for children at high risk. Immunotherapy is a treatment which "encourages the body to hunt down cancer cells and fight the disease".

The trail will take-on about 40 children who are currently classified in the high risk category, and they will then be given routine drugs and treatments like chemo, before being transferred to immunotherapy to track down remaining cancer cells.

The trail will be led by Dr Penelope Brock, a Consultant Pediatric Oncologist at Great Ormond Street Hospital, London.